Jason Rhodes

Jason Paul Rhodes is the founder of Disarm Therapeutics, Inc. (founded 2016), serving as Chairman from 2019 to 2020.
Mr. Rhodes is the founder of Dyne Therapeutics, Inc. (founded 2017), serving as Chairman since 2018.
Mr. Rhodes was the founder of F-Prime Inc. (founded 2001), serving as Partner from 2001 to 2007.
Mr. Rhodes was the founder of Generation Bio Co. (founded 2016), serving as Director from 2025 to 2026.
Mr. Rhodes currently serves as Executive Chairman at Rectify Pharmaceuticals LLC.
Mr. Rhodes is Director at Gemini Therapeutics Sub, Inc. since 2016.
Mr. Rhodes is Director at Accent Therapeutics, Inc. since 2017.
Mr. Rhodes is Director at Be Biopharma, Inc. Mr. Rhodes is Director at K36 Therapeutics, Inc. Mr. Rhodes is Partner at Atlas Venture Advisors, Inc. since 2014.
Mr. Rhodes is Partner at Atlas Venture Life Science Advisors LLC since 2014.
Mr. Rhodes is Board Member at AAVantgarde Bio Srl.
Former positions include Chief Executive Officer & Director at Raze Therapeutics, Inc. Independent Director at Bicycle Therapeutics Plc from 2015 to 2019.
Director at Zyngenia, Inc. Director at New England Venture Capital Association, Inc. Independent Director at Replimune Group, Inc. from 2015 to 2022.
Director at Third Harmonic Bio, Inc. Independent Director at Gemini Therapeutics, Inc. from 2016 to 2022.
Chief Financial Officer at FORUM Pharmaceuticals, Inc. Vice President of Business Development at Alnylam Pharmaceuticals, Inc. from 2007 to 2010.
President, Chief Financial Officer & Treasurer at Epizyme, Inc. from 2013 to 2014.
Partner at F-Prime Inc. from 2001 to 2007.
Education includes an undergraduate degree from Yale University conferred in 1991, an MBAistration from The Wharton School of the University of Pennsylvania conferred in 1996, and a doctorate from Harvard Medical School conferred in 2004.